Discover the current pipeline candidates advancing through the clinic for the treatment of sickle cell disease.

A recalled sickle cell drug is drawing new scrutiny from attorneys who say it may have done more harm than good, possibly ...

CMS is brokering outcomes-based agreements on behalf of Medicaid programs. Thirty-three states, along with Washington, D.C., ...

States representing about 84% of Medicaid beneficiaries are participating in an initiative that enables the U.S. government ...

According to Coherent Market Insights (CMI), the global sickle cell disease treatment market size is expected to expand from USD 3.20 Bn in 2025 to USD 8.81 Bn by 2032, recording a CAGR of 15.6% ...

So far in 2025, the Trump administration has cut more than $1 billion in NIH grants. That includes a study on sickle cell ...

CMS has reached agreements with drug manufacturers to provide gene therapies to treat sickle cell disease to Medicaid recipients under a new outcomes-based model. A total of 33 states, including the ...

The Centers for Medicare and Medicaid Services (CMS) has selected 35 participants for its new, voluntary Cell and Gene ...

The model was initially launched by the Biden administration in February 2023, and CMS announced that SCD would be the first focus of the model the following January. This is the ...

Families of those who have sickle cell disease in the Philadelphia area are pushing for more research and a cure.

Sickle cell disease affects about 100,000 people in the U.S., and 90% of patients are Black, according to NIH.

Sickle cell disease affects an estimated 100,000 people in the U.S. and the vast majority of them are Black. Federal and charitable dollars dedicated to sickle cell pale in comparison to other ...